

## **EmendoBio Inc. Announces Expansion of OMNI-A4™ Licensing Agreement with Anocca AB**

New York, USA, 4 September 2025 – EmendoBio Inc. (EmendoBio), an innovative gene editing company focused on the discovery and engineering of novel CRISPR nucleases for the development of gene edited therapeutics, today announced the expansion of its OMNI-A4™ non-exclusive licensing agreement with Anocca AB (Anocca), a leading clinical-stage T-cell immunotherapy company.

The expanded agreement builds upon the successful foundation established in March 2024, under which EmendoBio licensed its OMNI-A4™ nuclease to Anocca to accelerate the manufacture and development of Anocca's deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers. Under the terms of the new agreement, Anocca will expand the use of the OMNI-A4™ nuclease to knock-out and knock-in genes to further enhance its TCR-T product candidates.

"This expansion represents a significant milestone in our partnership with Anocca," said Ei Yamada, Chief Executive Officer at EmendoBio. "By broadening the scope of our collaboration, we are supporting Anocca's development of focused TCR-T cell therapies to address unmet patient needs."

"We are pleased to expand our collaboration with EmendoBio, enabling Anocca to deliver further innovative products from our deep TCR-T cell therapy pipeline" said Reagan Jarvis, Co-Founder and CEO at Anocca.

The financial details of the expanded agreement have not been disclosed.

### **About EmendoBio**

EmendoBio is a next-generation AI-based CRISPR gene editing company leveraging its proprietary technology to enable high precision gene editing, which is critical for the development of safe medical applications of genome editing. Driven by cutting-edge AI-based tools, novel gene editing strategies, and advanced protein engineering tools, EmendoBio's novel nuclease discovery platform broadens the targetable range of the genome, while its target-specific optimization platform enables highly precise editing with high efficiency.

EmendoBio's proprietary OMNI™ nucleases also are designed to reduce "off-target" effects, i.e., cleavage at locations other than the targeted genes. Achieving such pinpoint precision is a substantial challenge for genome editing therapies.

The capabilities of the OMNI™ technology platform, along with deep expertise in genomic medicine and protein engineering, provide EmendoBio with a unique advantage when addressing indications, including within hematology, cardiovascular, ophthalmology, oncology, and other disease areas.

View EmendoBio's service offerings at <https://www.emendobio.com>.

### **EmendoBio Inc.**

Noa Wertheimer

Tel: +972 54 6437741

[noaw@emendobio.com](mailto:noaw@emendobio.com)